已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters: pooled analysis of national prospective cohort studies of 30 million individuals in England, Northern Ireland, Scotland, and Wales

医学 接种疫苗 泊松回归 丹麦语 疫苗接种时间表 助推器(火箭) 人口学 2019年冠状病毒病(COVID-19) 人口 队列 儿科 增强剂量 环境卫生 免疫学 疾病 内科学 传染病(医学专业) 免疫 语言学 哲学 物理 天文 抗原 社会学
作者
Utkarsh Agrawal,Stuart Bedston,Colin McCowan,Jason Oke,Lynsey Patterson,Chris Robertson,Ashley Akbari,Amaya Azcoaga-Lorenzo,Declan T Bradley,Adeniyi Francis Fagbamigbe,Zoe Grange,Elliott Hall,Mark Joy,Srinivasa Vittal Katikireddi,Steven Kerr,Lewis Ritchie,Siobhán Murphy,Rhiannon K Owen,Igor Rudan,Syed Ahmar Shah,Colin Richard Simpson,Fatemah Torabi,Ruby S M Tsang,Simon de Lusignan,Ronan A Lyons,Dermot O'Reilly,Aziz Sheikh
出处
期刊:The Lancet [Elsevier]
卷期号:400 (10360): 1305-1320 被引量:3
标识
DOI:10.1016/s0140-6736(22)01656-7
摘要

Summary

Background

Current UK vaccination policy is to offer future COVID-19 booster doses to individuals at high risk of serious illness from COVID-19, but it is still uncertain which groups of the population could benefit most. In response to an urgent request from the UK Joint Committee on Vaccination and Immunisation, we aimed to identify risk factors for severe COVID-19 outcomes (ie, COVID-19-related hospitalisation or death) in individuals who had completed their primary COVID-19 vaccination schedule and had received the first booster vaccine.

Methods

We constructed prospective cohorts across all four UK nations through linkages of primary care, RT-PCR testing, vaccination, hospitalisation, and mortality data on 30 million people. We included individuals who received primary vaccine doses of BNT162b2 (tozinameran; Pfizer–BioNTech) or ChAdOx1 nCoV-19 (Oxford–AstraZeneca) vaccines in our initial analyses. We then restricted analyses to those given a BNT162b2 or mRNA-1273 (elasomeran; Moderna) booster and had a severe COVID-19 outcome between Dec 20, 2021, and Feb 28, 2022 (when the omicron (B.1.1.529) variant was dominant). We fitted time-dependent Poisson regression models and calculated adjusted rate ratios (aRRs) and 95% CIs for the associations between risk factors and COVID-19-related hospitalisation or death. We adjusted for a range of potential covariates, including age, sex, comorbidities, and previous SARS-CoV-2 infection. Stratified analyses were conducted by vaccine type. We then did pooled analyses across UK nations using fixed-effect meta-analyses.

Findings

Between Dec 8, 2020, and Feb 28, 2022, 16 208 600 individuals completed their primary vaccine schedule and 13 836 390 individuals received a booster dose. Between Dec 20, 2021, and Feb 28, 2022, 59 510 (0·4%) of the primary vaccine group and 26 100 (0·2%) of those who received their booster had severe COVID-19 outcomes. The risk of severe COVID-19 outcomes reduced after receiving the booster (rate change: 8·8 events per 1000 person-years to 7·6 events per 1000 person-years). Older adults (≥80 years vs 18–49 years; aRR 3·60 [95% CI 3·45–3·75]), those with comorbidities (≥5 comorbidities vs none; 9·51 [9·07–9·97]), being male (male vs female; 1·23 [1·20–1·26]), and those with certain underlying health conditions—in particular, individuals receiving immunosuppressants (yes vs no; 5·80 [5·53–6·09])—and those with chronic kidney disease (stage 5 vs no; 3·71 [2·90–4·74]) remained at high risk despite the initial booster. Individuals with a history of COVID-19 infection were at reduced risk (infected ≥9 months before booster dose vs no previous infection; aRR 0·41 [95% CI 0·29–0·58]).

Interpretation

Older people, those with multimorbidity, and those with specific underlying health conditions remain at increased risk of COVID-19 hospitalisation and death after the initial vaccine booster and should, therefore, be prioritised for additional boosters, including novel optimised versions, and the increasing array of COVID-19 therapeutics.

Funding

National Core Studies–Immunity, UK Research and Innovation (Medical Research Council), Health Data Research UK, the Scottish Government, and the University of Edinburgh.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
在水一方应助粥喝不喝采纳,获得10
1秒前
中和皇极给冰coke的求助进行了留言
3秒前
6秒前
午马未羊完成签到 ,获得积分10
9秒前
长江完成签到 ,获得积分10
9秒前
10秒前
JamesPei应助孤独树叶采纳,获得10
11秒前
11秒前
12秒前
赵晶晶完成签到,获得积分10
15秒前
adearfish完成签到 ,获得积分10
15秒前
凯凯宝发布了新的文献求助10
15秒前
小蘑菇应助托马斯亮绿采纳,获得10
16秒前
blossoms完成签到 ,获得积分10
16秒前
17秒前
献世应助凯凯宝采纳,获得10
20秒前
ding应助简单采纳,获得30
25秒前
25秒前
28秒前
30秒前
爱笑的毛衣完成签到,获得积分10
30秒前
锂炸发布了新的文献求助10
30秒前
科研通AI2S应助善良夜梅采纳,获得10
34秒前
ppg123应助最爱学习者采纳,获得10
35秒前
科研通AI2S应助最爱学习者采纳,获得10
35秒前
科研通AI2S应助最爱学习者采纳,获得10
35秒前
啦啦累完成签到,获得积分0
36秒前
刘佳婷完成签到,获得积分20
39秒前
KOKPA完成签到 ,获得积分10
40秒前
石狗西完成签到 ,获得积分10
41秒前
小二郎应助辛勤的沉鱼采纳,获得20
41秒前
科研通AI2S应助科研通管家采纳,获得10
41秒前
科研通AI2S应助科研通管家采纳,获得10
41秒前
华仔应助科研通管家采纳,获得10
41秒前
41秒前
科研通AI2S应助善良夜梅采纳,获得10
45秒前
飞驴完成签到,获得积分10
50秒前
简单完成签到,获得积分20
51秒前
小马甲应助dd99081采纳,获得200
52秒前
53秒前
高分求助中
The late Devonian Standard Conodont Zonation 2000
Nickel superalloy market size, share, growth, trends, and forecast 2023-2030 2000
The Lali Section: An Excellent Reference Section for Upper - Devonian in South China 1500
Smart but Scattered: The Revolutionary Executive Skills Approach to Helping Kids Reach Their Potential (第二版) 1000
Very-high-order BVD Schemes Using β-variable THINC Method 830
Mantiden: Faszinierende Lauerjäger Faszinierende Lauerjäger 800
PraxisRatgeber: Mantiden: Faszinierende Lauerjäger 800
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3248577
求助须知:如何正确求助?哪些是违规求助? 2892044
关于积分的说明 8269473
捐赠科研通 2560089
什么是DOI,文献DOI怎么找? 1388851
科研通“疑难数据库(出版商)”最低求助积分说明 650913
邀请新用户注册赠送积分活动 627798